investors

Press Releases

DateTitle and SummaryView
December 14, 2015
LOS ANGELES , Dec. 14, 2015 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced the establishment of an agreement with a major Canadian cancer cooperative group, The Canadian Brain Tumour Consortium (CBTC), for the phase 3 registrational trial of
ImmunoCellular Therapeutics Establishes Agreement with The Canadian Brain Tumour Consortium for ICT-107 Phase 3 Registrational Trial in Glioblastoma
December 7, 2015
Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation NEW YORK , Dec. 7, 2015 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC), today announced that the December 3
ImmunoCellular Therapeutics Presentation Now Available for On-Demand Viewing
December 7, 2015
LOS ANGELES , Dec. 7, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced the establishment of an agreement with a major cancer research group, Alliance Foundation Trials, LLC (AFT), for the phase 3 registrational trial of its cancer
ImmunoCellular Therapeutics Establishes Agreement with Alliance Foundation Trials, LLC for ICT-107 Phase 3 Registrational Trial in Glioblastoma
December 1, 2015
Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com NEW YORK , Dec. 1, 2015 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that Andrew Gengos ,
ImmunoCellular Therapeutics to Webcast, Live, at VirtualInvestorConferences.com December 3
December 1, 2015
LOS ANGELES , Dec. 1, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) announced today the establishment of an agreement with the European Organisation for Research and Treatment of Cancer (EORTC) for the phase 3 registrational trial of ICT-107 in
ImmunoCellular Therapeutics Establishes Agreement with EORTC for ICT-107 Phase 3 Registrational Trial in Glioblastoma
November 23, 2015
LOS ANGELES , Nov. 23, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it plans to host a conference call and webcast at 4:30 pm ET on Tuesday, November 24, 2015 to discuss the ICT-107 program in patients with newly diagnosed
ImmunoCellular Therapeutics to Host Conference Call and Webcast to Discuss ICT-107 Program in Newly Diagnosed Glioblastoma on November 24, 2015
November 20, 2015
Data support phase 3 registration trial incorporating key design modifications to potentially optimize outcomes
ImmunoCellular Therapeutics Presents Updated ICT-107 Phase 2 Survival and Immune Response Data at the Society for Neuro-Oncology Annual Meeting 2015
November 12, 2015
LOS ANGELES , Nov. 12, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced it has entered into a sponsored research agreement with Dr. Cassian Yee at the University of Texas MD Anderson Cancer Center. Dr.
ImmunoCellular Therapeutics Enters into Sponsored Research Agreement with University of Texas MD Anderson Cancer Center to Advance Stem-to-T-Cell Program
November 10, 2015
ICT-107 Phase 3 Registration Trial Expected to be Initiated in November
ImmunoCellular Therapeutics Announces Third Quarter 2015 Financial Results
October 27, 2015
LOS ANGELES , Oct. 27, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it plans to report financial results for the third quarter 2015 on Tuesday, November 10, 2015 . The Company also plans to hold a conference call and webcast on
ImmunoCellular Therapeutics to Report Third Quarter 2015 Financial Results on November 10, 2015
Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved